ZA836582B - Constant release rate solid oral dosage formulations of drugs having a pka7-10 and an aqueous solubility of 15-100g/ml water - Google Patents

Constant release rate solid oral dosage formulations of drugs having a pka7-10 and an aqueous solubility of 15-100g/ml water

Info

Publication number
ZA836582B
ZA836582B ZA836582A ZA836582A ZA836582B ZA 836582 B ZA836582 B ZA 836582B ZA 836582 A ZA836582 A ZA 836582A ZA 836582 A ZA836582 A ZA 836582A ZA 836582 B ZA836582 B ZA 836582B
Authority
ZA
South Africa
Prior art keywords
oral dosage
release rate
solid oral
pka7
weight percent
Prior art date
Application number
ZA836582A
Other languages
English (en)
Inventor
James Michael Dunn
Original Assignee
Verex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verex Lab filed Critical Verex Lab
Publication of ZA836582B publication Critical patent/ZA836582B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA836582A 1983-01-03 1983-09-05 Constant release rate solid oral dosage formulations of drugs having a pka7-10 and an aqueous solubility of 15-100g/ml water ZA836582B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/455,192 US4461759A (en) 1983-01-03 1983-01-03 Constant release rate solid oral dosage formulations of veropamil

Publications (1)

Publication Number Publication Date
ZA836582B true ZA836582B (en) 1984-04-25

Family

ID=23807768

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA836582A ZA836582B (en) 1983-01-03 1983-09-05 Constant release rate solid oral dosage formulations of drugs having a pka7-10 and an aqueous solubility of 15-100g/ml water

Country Status (8)

Country Link
US (1) US4461759A (de)
EP (1) EP0120118B1 (de)
JP (1) JPS59128323A (de)
AT (1) ATE41739T1 (de)
AU (1) AU1810783A (de)
CA (1) CA1201064A (de)
DE (1) DE3379496D1 (de)
ZA (1) ZA836582B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US5560909A (en) * 1986-06-03 1996-10-01 Dowelanco Insecticidal compositions and process for preparation thereof
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4851233A (en) * 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5093198A (en) * 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
DE4127665A1 (de) * 1991-08-22 1993-02-25 Beiersdorf Ag Galenische matrix
DK0701434T3 (da) * 1993-06-04 2002-11-18 Warner Lambert Co Præparater indeholdende siliciumdioxid til forbedring af deres smag
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US20040259895A1 (en) * 1998-05-28 2004-12-23 Medical Research Institute Oral formulation of lipid soluble thiamine and lipoic acid
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
DE60000022T2 (de) * 1999-03-05 2002-03-14 Rohm And Haas Co., Philadelphia Verbesserte teilchenförmige Zusammensetzungen
RU2145214C1 (ru) * 1999-07-08 2000-02-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция, обладающая сердечно-сосудистым действием
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
RU2166650C1 (ru) * 2000-03-03 2001-05-10 Смольский Любомир Асафатович Двигатель внутреннего сгорания
WO2002024191A1 (fr) * 2000-09-20 2002-03-28 Yong Guang Pharmaceutical Co., Ltd. Medicament permettant de traiter et de prevenir la myopie
JP2005515966A (ja) * 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ, インコーポレイティド 鎮痛薬としての使用のための6−ヒドロキシ−オキシモルホンの経口投与
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EP1492511B3 (de) 2002-04-09 2012-05-02 Flamel Technologies Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1686967A4 (de) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
CA2547137A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
DE602004022205D1 (de) * 2004-09-09 2009-09-03 Psicofarma S A De C V Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie
US20080132444A1 (en) * 2004-10-09 2008-06-05 Xiaoling Li Ocular Agent Delivery Systems
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ,イサ オルガノゾル被膜を含む制御放出送達デバイス
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742467A (en) * 1953-07-08 1956-04-17 Cassella Farbwerke Mainkur Ag Hypotensive drugs
CH415963A (de) * 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3577514A (en) * 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
SE7504049L (sv) * 1975-04-09 1976-10-10 Haessle Ab Colonpreparation
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
DE3113901A1 (de) * 1981-04-07 1982-10-28 Basf Ag, 6700 Ludwigshafen Wirkstoffzubereitung zur oralen applikation

Also Published As

Publication number Publication date
US4461759A (en) 1984-07-24
EP0120118B1 (de) 1989-03-29
AU1810783A (en) 1984-09-06
EP0120118A1 (de) 1984-10-03
CA1201064A (en) 1986-02-25
ATE41739T1 (de) 1989-04-15
JPS59128323A (ja) 1984-07-24
DE3379496D1 (en) 1989-05-03

Similar Documents

Publication Publication Date Title
ZA836582B (en) Constant release rate solid oral dosage formulations of drugs having a pka7-10 and an aqueous solubility of 15-100g/ml water
NO20022264D0 (no) Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav
NZ295211A (en) Topical aqueous gel containing a water-soluble cellulose derivative, propylene glycol & drug(s) for haemorrhoids
YU66600A (sh) Farmaceutski preparati koji mogu da budu gelirani
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR890009376A (ko) 분무 건조된 이부프로펜
EP0221041A3 (de) Benzimidazolderivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
BG50924A3 (bg) Метод за получаване на фармацевтичен състав
FR2712807B1 (fr) Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
IL109534A0 (en) Pour-on formulations containing polymeric material, glycols and glycerides and a process for their preparation
CA2005987A1 (en) Therapeutically active substituted benzimidazole and process for its preparation
IL92799A0 (en) Benzimidazole derivatives with gastric acid inhibition and process for its preparation
DE3764111D1 (de) Arzneimittelkombination.
IT1151953B (it) Composizione farmaceutica per la cura di affezioni della cavita' orale
SE8600496L (sv) Farmaceutiska kompositioner innehallande 9,10-dihydroergotalkaloider
CA1163558A (en) Medicament capsules for rectal application
SE8004383L (sv) Farmaceutisk beredning for oral administrering och forfarande for dess framstellning
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
EP0147883A3 (de) Wässrige nichtaggressive anthelmintische "pour-on"-Formulierungen
FR2750859B1 (fr) Composition pharmaceutique destinee a une administration par voie buccale avec absorption d'au moins un principe actif a travers les muqueuses de la bouche
EP0011868A1 (de) Methyldopa-Zusammensetzung
IE873463L (en) Compositions
KR880005094A (ko) 치료제 조성물 및 이의 용도
BE904737A (fr) Derives de l'acide octenoique.
IT1142260B (it) L-alanina come agente farmaceutico impiegato per la cura di cerebropatie vascolari e relative formulazioni